Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study by Baddeley, Elin et al.
1Baddeley E, et al. BMJ Open 2020;10:e039154. doi:10.1136/bmjopen-2020-039154
Open access 
Development of a core outcome set to 
use in the research and assessment of 
malignant bowel obstruction: protocol 
for the RAMBO study
Elin Baddeley   ,1 Alison Bravington,2 Miriam Johnson,2 David C Currow,2,3 
Fliss EM Murtagh,2 Elaine Boland,4 George Obita,5 Annmarie Nelson,1 
Kathy Seddon,1 Alfred Oliver,6,7 Simon Noble,1 Jason Boland   2
To cite: Baddeley E, 
Bravington A, Johnson M, et al.  
Development of a core outcome 
set to use in the research 
and assessment of malignant 
bowel obstruction: protocol for 
the RAMBO study. BMJ Open 
2020;10:e039154. doi:10.1136/
bmjopen-2020-039154
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
039154).
Received 06 April 2020
Revised 22 May 2020
Accepted 29 May 2020
For numbered affiliations see 
end of article.
Correspondence to
Elin Baddeley;  
 baddeleye1@ cardiff. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Studies regarding the management of 
malignant bowel obstruction (MBO) report conflicting 
findings. This is partly due to different outcome measures 
being used to evaluate severity of MBO and the response 
to treatments. Furthermore, current outcome measures 
focus mainly on measurable physiological parameters 
which may not correlate strongly with patient- defined 
quality of life. The development of core outcome sets 
allows a consistent approach to evaluating clinical 
conditions taking into consideration patient, healthcare 
professional and researcher viewpoints. It follows an 
internationally recognised standard methodology. We 
present a protocol for the development of a core outcome 
set for Research and Assessment of MBO (RAMBO).
Methods RAMBO is a multicentre study, comprising 
of four phases: a systematic review to examine current 
scope of outcome measures associated with MBO (phase 
I). Interviews with patients, companions and healthcare 
professionals will explore priorities and preferences for 
care and outcomes (phase II). An expert panel meeting 
will collate the findings into a set of outcomes (phase 
III), refined by consensus through a Delphi survey with 
key stakeholders (phase IV). The final set of outcomes 
will be ratified at a consensus meeting. Each step will 
actively include patient partners. Thematic analysis and 
descriptive statistics will be used to analyse qualitative 
and quantitative data, respectively.
Ethics and dissemination Ethical approval was obtained 
(Wales REC 5, REF: 19/LO/1876). Study participants and 
relevant stakeholders will be updated with newsletters and 
a lay summary at the end of the study. Abstracts will be 
submitted to national and international conferences, result 
papers will be submitted to peer- reviewed, open access 
journals.
trial and PrOsPErO registration numbers Core 
Outcome Measures in Effectiveness Trials (1402); 
Systematic Literature Review (CRD42019150648); Rapid 
Review (CRD42020176393).
IntrOduCtIOn
Malignant bowel obstruction (MBO) is bowel 
obstruction due to cancer or its treatments. 
It primarily affects people with advanced 
ovarian (10%–50%) and gastrointestinal 
cancers (15%) and remains a challenging 
condition facing oncology, surgical, gynae-
cology, gastroenterology and palliative care 
teams.1 2 It is one of the most distressing 
complications of cancer, causing nausea, 
vomiting, abdominal distension, colic, pain 
and constipation.3–8 It also has a persistent 
and profound effect on quality of life9 and 
often requires hospitalisation for persistent 
unresolved symptoms.3
Management options for MBO in patients 
with advanced cancer are limited; some, 
usually those with a single- level bowel 
obstruction, may be offered surgery to resect 
an isolated tumour or create a defunctioning 
stoma. Some people may benefit from the 
endoscopic placement of a stent for palli-
ative purposes. However, the majority of 
strengths and limitations of this study
 ► This is the first study to develop a core outcome set 
for the evaluation of malignant bowel obstruction.
 ► The protocol follows a well- established process 
following Core Outcome Measures in Effectiveness 
Trials guidelines, including a thorough systematic 
review, qualitative rapid review, semistructured in-
terviews with patients, their companions and health-
care professionals, followed by a three- step Delphi 
survey.
 ► The study outcomes will reflect what is important 
to patients and their companion/carers as well as 
clinicians and researchers.
 ► Patient partner involvement (PPI) for this study ad-
heres to the UK PPI standards and has occurred from 
the inception of the study, particularly the method-
ology, including data collection tools for patient and 
companion interviews.
 ► Since the qualitative data collection will occur in the 
UK, there may be limitations on how applicable the 
outcome measures will be if applied internationally.
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cases present with multiple level obstructions which are 
not amenable to surgical or endoscopic interventions. 
Pharmacological approaches for symptom reduction 
in inoperable MBO (IMBO) usually involve a combina-
tion of antiemetics and parenteral antisecretory agents 
(anticholinergics, somatostatin analogues and H2 antago-
nists), often with gut decompression (nasogastric tube or 
venting gastrostomy).10 11
Current evidence informing the symptom management 
of IMBO is inadequate; clinical guidelines favour soma-
tostatin analogues but recommendations have been based, 
largely, on case series and insufficiently powered clinical 
trials.9 Recently, two adequately powered, well- conducted 
clinical trials demonstrated no objective benefit, with 
one of them suggesting evidence of harm.4 12 Impor-
tantly, these two trials included a placebo arm to reflect 
the natural history of IMBO, which is largely unknown, 
except that spontaneous resolution with recurrence is 
common and, for many people, it appears that vomiting 
will generally lessen in frequency and volume with time. 
However, these trials do not appear to have impacted on 
subsequent guidelines or clinical recommendations13–16 ; 
although there are some data showing they have affected 
clinical practice.17
A recent systematic review of somatostatin analogues, 
using objective tools to evaluate data quality, concluded 
that there was moderate evidence of no benefit and only 
poor evidence for their use.18 The authors suggested 
that the most significant challenge in evaluating current 
data lays with the many studies using differing clinical 
outcomes, thereby making it impossible to objectively 
compare study outcomes or submit them to meta- analysis. 
The lack of an agreed core outcome set (COS) for MBO 
has considerable challenges in ensuring consistent clin-
ical and research evaluation of interventions for patients 
with MBO.
Identifying outcome measures that reflect real-world settings
In order to ensure that outcome measures are relevant 
to patients, it is essential to have patients at the frontline 
of the research in order to ascertain their quality of life 
and preferences for symptom management and care. 
Patient- reported outcomes, when collected and analysed 
appropriately, are key to shared decision- making, clinical 
guidelines and health policy.19 Involving patients’ views 
and understanding the challenges they face are invalu-
able in understanding how care happens in real- world 
settings, otherwise trials might fail to account for the 
outcomes that matter most to patients.20
rationale of COs development for MbO
A key issue identified on both national and international 
levels is the lack of data indicating how primary outcome 
measures used to evaluate MBO related to patient expe-
rience.1 17 For example, measures of symptom relief may 
not directly reflect what is important to patients and their 
companions (next of kin/carers) and what they consider 
to be meaningful.18
The broad and varied approaches to outcome measure-
ment in the palliation of MBO, and the lack of an evidence 
base for patient- relevant measures, have led to a diversity 
of approach in clinical trials and inconsistent recommen-
dations in clinical guidelines. Importantly, the continua-
tion of poorly evidenced clinical practice may also cause 
harm.21 Recent publications have called for the develop-
ment of a COS, to ensure uniformity of symptom assess-
ment within clinical trials and clinical practice.21 This 
study aims to address this gap. It will ascertain patients’ 
perceptions of the management of their condition, 
compare these with outcomes measured in the current 
literature and gain consensus on an agreed set of core 
outcomes to be used in clinical practice to streamline 
appropriate and targeted management of MBO.
Aims
The Research and Assessment Outcome Measures for 
MBO (RAMBO) study aims to review the current scope of 
outcome measures used to evaluate MBO and to develop 
a set of core outcomes specific to MBO. It will ask the 
following questions:
 ► What outcome measures are currently used to eval-
uate MBO within the context of clinical research and 
clinical practice?
 ► What symptoms and effects do patients with MBO, 
their companions and healthcare professionals 
consider most important, and what improvement 
would they consider clinically meaningful?
 ► How do currently used outcomes map to those factors 
identified as important by patients, their companions 
and healthcare professionals, and what are the gaps 
and limitations in current measures?
MEthOds
study design
We propose to use a multiphase, mixed- method, multi-
centre study to address the research questions. In phase 
I, a systematic literature review (SLR) will be conducted 
to identify outcomes currently used to evaluate MBO. 
Phase II will comprise of interviews with patients, their 
companions and healthcare professionals to understand 
their experiences, priorities and preferences for care. 
The findings of these two phases will inform phase III, 
an expert panel meeting, to direct the compilation of a 
comprehensive list of outcomes which will feed into the 
phase IV Delphi survey, a two- round ranking exercise 
followed by a consensus meeting. The aim of the Delphi 
is to achieve consensus on a final COS. A summary of the 
design is seen in figure 1. Dissemination will follow the 
COS- STAndards for Reporting Statement.22
Patient and public involvement
We actively support the fundamental involvement of 
patient and public involvement as set out by the UK Stan-
dards for Public Involvement in research in all of our 
research.23 The RAMBO study has recruited two research 
partners (one of who is a coapplicant on the study) to 
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Figure 1 Process for the development of a core outcome set (COS) for malignant bowel obstruction (MBO).
represent lay stakeholders in the study management 
group advising on recruitment and participant- facing 
documentation. They will also contribute to thematic 
analysis of the interview data. Lay representatives will also 
be involved in the interpretation and dissemination of 
the study results.
Phase I: sLr
The Core Outcome Measures in Effectiveness Trials 
(COMET) Initiative recommends an SLR as an initial 
phase in studies developing COS.22 This will identify all 
outcomes used in clinical trials and observational studies 
in patients undergoing palliative treatment for inoper-
able MBO. Qualitative papers will not be included as they 
do not quantify outcomes, but a separate, rapid review of 
qualitative studies will inform the writing up of the phase 
II interview study (see below). Databases to be searched 
include MEDLINE, EMBASE, CINAHL, CareSearch 
and the Cochrane Central Register of Controlled Trials. 
Other sources will include reference lists of included 
articles and of previous systematic reviews of MBO inter-
ventions, conference proceedings, grey literature and the 
authors’ own files. No date or language restrictions will 
be imposed.
The research questions that the review seeks to answer 
are:
 ► What outcome measures are used to evaluate clinical, 
symptomatic and psychological aspects of MBO within 
the context of clinical research and practice?
 ► How is the timing of outcome measures justified?
 ► Which outcome measures should be considered for 
inclusion in a COS for future clinical trials?
A broad range of study designs and heterogeneous data 
are anticipated in papers meeting the inclusion criteria 
for this review, and data will be explored using narrative 
synthesis. The review will record all clinical, symptomatic 
and psychological outcomes reported in the included 
studies, with the definitions and time points of each 
measure, and will review their heterogeneity and their 
relevance to patients with MBO. Data will be extracted 
and grouped with reference to the outcome taxonomy 
recommended by COMET. The full protocol for the 
review, including the search strategy and study selection 
criteria, is available on the PROSPERO database.
Phase II: interviews with patients, their companions and 
healthcare professionals
Participant eligibility and sampling
Interviews will explore the experiences of approxi-
mately 15 patients with MBO, what outcomes they would 
most value from their care and the experiences of their 
companion if possible. In this case, companion if defined 
as a significant informal carer or family member (aged 
over 18). Patients eligible for interview will be adults aged 
18 or more with histologically confirmed cancer, with 
their MBO currently or recently resolved but with risk of 
recurrence, as confirmed by either two senior medical 
practitioners or one medical practitioner in combination 
with confirmatory radiology. Patients will be interviewed 
with their carer/companion present if this is the patient’s 
 o
n




pen: first published as 10.1136/bmjopen-2020-039154 on 28 June 2020. Downloaded from 
4 Baddeley E, et al. BMJ Open 2020;10:e039154. doi:10.1136/bmjopen-2020-039154
Open access 
preference; carers/companions will be interviewed sepa-
rately where this is preferred. We will not include patients 
who have any diagnosed medical problems that would 
prohibit them from participating in a 30 min to 1 hour 
interview.
We will also interview approximately 15 healthcare 
professionals from a breadth of clinical specialities 
involved in the care of patients with MBO at the recruit-
ment sites in the 12 months prior to recruitment, to 
explore the experiences involved in the management 
of MBO. Healthcare professionals will be purposively 
sampled to ensure a breadth of clinical specialties 
involved in the management of MBO, including primary 
care, palliative care, oncology, colorectal and gynaecolog-
ical surgery.
The sample size of participants is based on the past 
experience of patients receiving palliative care services 
across multiple studies and aims to reach data satura-
tion—the point at which no new topics emerge. This 
will be achieved by constant reevaluation and discussion 
between the two interviewers and with input from the 
study management team.
Data collection
A semistructured interview format will be used to explore 
patients’ understanding, experiences and symptoms of 
MBO, what matters most to patients with MBO and what 
they consider to be a meaningful improvement regarding 
the relief of MBO symptoms. Interviews conducted with 
healthcare professionals will explore their experiences of 
managing MBO, how they evaluate severity and symptom-
atic response to treatment, what they perceive matters 
most to patients in regard to treatment of MBO and how 
they perceive ‘meaningful improvement’ in a patient with 
MBO.
Interviews are expected to last between 30 min and 
1 hour. They will be undertaken in a quiet location at 
participating hospitals or hospices or an alternative loca-
tion of the participants’ choice, at a time specified by the 
participant.
Interviews will be audio recorded on an encrypted 
recording device (with the participants’ consent) and 
uploaded onto a secure server, labelled with an identi-
fying code, with no reference to personal details. Audio 
files will be transcribed verbatim by an authorised agency. 
Basic demographic data will be collected and reported 
descriptively but not used as sampling criteria. Transcripts 
will be checked to ensure anonymisation by a member of 
the research team before being uploaded to NVivo V.1224 
qualitative software for data management.
Consent
Written consent will be obtained at the outset of each 
interview. Individuals who lack the capacity to consent 
will not be included in this study. Participant informa-
tion sheets will be distributed to potential participants 
by their clinical team, to give participants the time to 
make an informed decision whether or not they wish to 
participate. If they choose to participate, they will inform 
a member of their clinical team, who will pass on the 
patients’ contact details to the researcher or the patient 
can contact the researcher directly. The researcher will 
take written consent before the interview commences; 
participants will have the chance to ask questions before 
the interview, and it will be stressed to the participant that 
they are under no obligation to take part and may with-
draw from the study at any point during the interview, 
and that their participation has no influence on their 
medical care.
Healthcare professionals will be invited by email to 
participate in the study, with a follow- up email after 1 week; 
eligible participants will be identified by the clinical team, 
and the email will provide them with a participant infor-
mation sheet. If a potential participant expresses interest, 
they will be asked to contact the researcher directly or 
asked permission for the researcher to contact them. An 
interview slot will be arranged at an appropriate time for 
the individual and written consent will be taken by the 
researcher.
Data analysis
Thematic analysis25 will be used to interrogate the inter-
view data. Analysis will be conducted by two researchers, 
with experience in qualitative research, but no fixed views 
regarding the management or assessment of MBO. After 
an initial period of independent coding, meetings will be 
held between the two researchers to refine the themes 
and their concomitant categories. The analysis frame-
work will be iteratively refined until all transcripts have 
been coded and a final thematic framework produced.25
Findings from phase I (SLR) and phase II (interviews) 
will be summarised in a report which addresses the main 
research question: what issues do patients, their compan-
ions and healthcare professionals consider to be most 
important in the management of symptoms of MBO, and 
what improvements would they consider meaningful? 
These data will also be synthesised with the qualitative 
data (phase- II interviews) identified through a rapid 
review of the qualitative literature. The report will seek 
to identify significant experiences and priorities among 
patients, their carers (if present) and healthcare profes-
sionals, that align with measurable outcomes,23 and can 
be taken forward into the initial outcomes list presented 
in phase III.
Phase III: steering meeting and expert panel
A steering meeting will be held to consolidate the find-
ings of the SLR and interview study, to produce a list 
of outcomes to be taken forward into round 1 of the 
Delphi. The outcome list will be discussed and refined 
by an expert panel (consisting of approximately 10 
academics/patient or carer research partners/healthcare 
professionals chosen for their recognised expertise in 
and/or experience of MBO), following Conducting and 
REporting DElphi Studies (CREDES) in palliative care 
guidelines for the Delphi technique.26
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Phase IV: delphi survey
The Delphi survey will be carried out using Online Survey 
UK, an electronic bespoke survey format, which has previ-
ously been developed by the COMET Initiative for the use 
in COS development projects. A piloting round will be 
conducted with expert and lay members of the steering 
panel prior to wider stakeholder involvement. If issues 
needing resolution arise from this process, a second pilot 
round will be included. The survey will present the list 
of outcomes to stakeholders in two rounds, with a final 
consensus meeting to resolve points of difference. The 
aim of the process is to reach consensus, taking in a range 
of viewpoints: stakeholders will include patient represen-
tatives and healthcare professionals in the area of clinical 
oncology, colorectal surgery, gastroenterology, gynaeco-
logical surgery and specialist nursing. Anonymous results 
from the first round will be circulated between all stake-
holder groups as a basis for the subsequent round of 
decision- making. Items on which the agreed threshold of 
consensus is reached in round 1 will be dropped from 
round 2. This technique is recognised by the COMET 
Initiative as appropriate to the development of COS.23 27
Recruitment
Identification of potential patient research partners will 
take place in tandem with recruitment for phase II of the 
study, via the same recruitment channels, and through 
formal carer or bereavement groups run by voluntary 
organisations. Healthcare professionals will be recruited 
from hospitals and hospices and by using the authors’ 
professional networks. Participants will be recruited 
through telephone, email or post. No new participants 
will be invited following the completion of round 1.
Based on the recruitment numbers in the previous 
studies and a pragmatic approach to reaching 
consensus,28 29 we will aim to recruit a minimum of 40 
respondents to take part, including patients/compan-
ions, healthcare professionals and policy. Consent will 
be implicit through the participants’ registration to take 
part and completion of the survey. Each participant will 
be represented in the survey documents by a unique iden-
tifier label; personal details will be kept confidential in a 
separate database on secure online storage.
Delphi process
The outcome list produced during phase III will be used 
to construct the Delphi survey. Panel members will be 
asked to score each outcome on a Likert scale ranging 
from 1 to 927 (1–3—limited importance; 4–6—important 
and 7–9—critically important), relative to the other 
outcomes, in terms of the following question:
 ► Please consider each listed outcome and rate how 
important it is to measure a change in the outcome 
when providing palliative care to address the symp-
toms of MBO?
In addition to scoring outcomes, free text boxes will 
allow comments to be gathered on each item in each 
round of the survey, to make decision- making visible and 
assist other participants to refine their decision- making in 
the following round. This will allow respondents to add 
additional outcomes in order to address any perceived 
gaps in the way that patients’ experiences are measured.
We anticipate two rounds to refine and rank outcomes 
in order to reach consensus, followed by a consensus 
meeting to resolve any items on which agreement is not 
reached. For each outcome in each round, the distribu-
tion of scores will be summarised, and items scored as of 
limited importance by all respondents will be dropped 
from subsequent rounds; all other items will be carried 
forward. The preset agreement criterion for scoring 
outcomes at each stage will be ≥70%, based on the 
previous studies describing the development of COS.30 31 
Consensus will be reached if the majority of participants 
score a specific outcome similarly. Three categories will 
be assigned for each outcome:
 ► Consensus: in—70% or more respondents within 
a stakeholder group rate the outcome as critically 
important and 15% or fewer rate the outcome as of 
limited importance.
 ► Consensus: out—70% or more of participants rated 
an outcome as of limited importance and 15% or 
fewer rated the outcome as critically important.
 ► No consensus—none of the above criteria is met.
If 70% or more of the respondents agree that an 
outcome is of low importance in round 1, this item will be 
dropped from round 2. If 70% or more of respondents 
agree that an outcome is of high importance in round 
1, this item will be dropped from round 2 and will be 
proposed for inclusion in the final COS. All other items 
will be carried forward. In round 2, participants will be 
shown the number of respondents and distribution of 
scores for each remaining outcome from all stakeholder 
groups, with their own score from round 1. They will be 
asked to consider the responses from other Delphi partic-
ipants and to rescore the items. If a participant changes 
their score from of limited importance (<4 in round 1) 
to critically important in round 2 (7 or more) or from 
critically important in round 1 to of limited importance 
in round 2, they will be asked to provide the reason for 
this change. We will also examine any other changes in 
scores between rounds and summarise reasons given for 
these changes.
Items on which agreement was not reached will be 
discussed and resolved at the final consensus meeting. 
Outcomes from the Delphi survey classed as ‘consensus 
in’ across all groups will be proposed for inclusion in the 
final COS; outcomes classed as ‘consensus out’ will be 
proposed for exclusion.
Consensus meeting
All Delphi participants will be eligible for inclusion in a 
face- to- face consensus meeting to achieve a final recom-
mendation of a core set of outcomes. The survey registra-
tion page for round 1 will ask participants to tick a box 
to allow the study team to approach them for inclusion. 
Appropriate secondary stakeholder groups recommended 
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by existing stakeholders will be invited to take part at this 
stage. Written consent will be taken at the outset of the 
meeting from all participants to audio record the discus-
sion; the audio file will be transcribed and anonymised. 
Participants will discuss all outcomes and their status at 
the close of the survey. They will then vote on an outcome- 
by- outcome basis to confirm consensus or to suggest that 
an outcome requires further discussion. Further voting 
rounds will be conducted as necessary until the final 
outcome set is agreed.
EthICAL COnsIdErAtIOns
Ethical approval for the study was obtained on 10 
December 2019, from Wales Research Ethics Committee 
5 Bangor (REF: 19/LO/1876). All data will be collected 
according to the principles of the General Data Protec-
tion Regulations and Data Protection Act 2018.32
dIssEMInAtIOn
The study is registered with the COMET database and 
dissemination through this will complement peer- review 
publications. Study participants and relevant bodies (eg, 
healthcare professionals involved in the management 
of MBO—including palliative care, gynaecology and 
colorectal surgery and patient partner organisations) will 
be regularly updated with newsletters and a lay summary 
at the end of the study. We will disseminate the research 
findings widely. Abstracts will be submitted to national 
and international conferences, result papers will be to 
relevant stakeholders at international conferences and 
submitted to publish in high- impact, open access jour-
nals. Dissemination will be undertaken with professional 
organisations such as the Association of Palliative Medi-
cine, European Association for Palliative Care, The Multi-
national Association of Supportive Care in Cancer, The 
American Society of Clinical Oncology, The European 
Society for Medical Oncology, National Cancer Research 
Institute and Hospice UK to adopt the recommendations 
from the work. Lay summaries will be uploaded on the 
Marie Curie website, including the Marie Curie Palliative 
Care Research Centre (MCPCRC)- specific website and 
Wolfson Palliative Care Research Centre websites, and 
sent to key PPI groups and disseminated via social media.
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